Start-Up Archer Preps Alzheimer’s Drugs For Phase I
This article was originally published in The Pink Sheet Daily
IND filed, company aims to use nilvadipine derivative against soluble amyloid.
You may also be interested in...
Wyeth/Elan's Phase II bapineuzumab trial for Alzheimer's disease did not impress investors, but the sponsors are convinced they made the right bet in how they designed the study
In Part I of a series, panelists discuss outcomes measures in a sector with unique regulatory conditions and the need for biomarkers.
But study published in Lancet raises questions about efficacy of anti-amyloid therapy.